Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus
Why the study?
Does canagliflozin reduce cardiovascular death or hospitalized HF in patients with type 2 diabetes mellitus and high cardiovascular risk?
Population
10,142 participants with type 2 diabetes mellitus and high cardiovascular risk
Comparison
Canagliflozin vs Placebo
Design
RCT, randomly assigned
Follow-up
mean of 188 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports canagliflozin use for HF prevention in high-risk T2DM; confirms SGLT2i class benefit on HF outcomes in RCTs.
Structured PICO
Does canagliflozin reduce cardiovascular death or hospitalized HF in patients with type 2 diabetes mellitus and high cardiovascular risk?
P
Population
10,142 participants with type 2 diabetes mellitus and high cardiovascular risk
I
Intervention
Canagliflozin
C
Comparator
Placebo
O
Outcome
Adjudicated cardiovascular death or hospitalized HFcomposite
Canagliflozin reduces the risk of cardiovascular death or hospitalized heart failure in patients with type 2 diabetes and high cardiovascular risk, with potentially greater benefits in those with a history of heart failure.
Cite This Study
Rådholm et al. (2018) studied this question.